Levonorgestrel-releasing intrauterine device (LNG-IUD) for symptomatic endometriosis following surgery
article
OA: closed
CC0
⤵ 50 in-corpus citations
AI-generated summary
Postoperative levonorgestrel-releasing intrauterine device insertion in women with endometriosis showed a reduced recurrence of painful periods compared to expectant management.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
BACKGROUND: Various options exist for treating endometriosis, including surgical, medical, such as ovarian suppression, or a combination of these strategies. Surgical treatment of endometriosis aims to remove visible areas of endometriosis. The aim of medical therapy is to inhibit growth of endometriotic implants by induction of a hypo-estrogenic state. Treatment with a hormone-releasing intrauterine device, using levonorgestrel (LNG-IUD), has also been suggested. OBJECTIVES: To determine whether postoperative LNG-IUD insertion in women with endometriosis improves pain and reduces recurrence of symptoms compared with no postoperative treatment, postoperative insertion of a placebo, or postoperative therapy. SEARCH METHODS: The following databases were searched from inception to June 2012: Cochrane Menstrual Disorders and Subfertility Group Specialised Register of controlled trials, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, PsycINFO, CINAHL, and the World Health Organization (WHO) International Clinical Trials Registry Platform. EMBASE was searched from 2010 to June 2012. The citation lists of relevant publications, review articles, abstracts of scientific meetings, and included studies were also searched. SELECTION CRITERIA: Trials were included if they compared women undergoing surgical treatment for endometriosis with uterine preservation and then randomised within three months to LNG-IUD insertion versus no postoperative treatment, placebo (inert IUD), or other treatment. Diagnostic laparoscopy alone was not considered suitable treatment. DATA COLLECTION AND ANALYSIS: Two review authors independently selected studies for inclusion and extracted data to allow for an intention-to-treat analysis. For dichotomous data, the risk ratio (RR) and 95% confidence interval (CI) were calculated using the Mantel-Haenszel random-effects method. For continuous data, the mean difference (MD) and 95% CI were calculated using the inverse variance random-effects method. MAIN RESULTS: Three randomised controlled trials were included. In two trials, there was a statistically significant reduction in the recurrence of painful periods in the LNG-IUD group compared with expectant management (RR 0.22, 95% CI 0.08 to 0.60, 95 women, I(2) = 0%, moderate strength of evidence). The proportion of women who were satisfied with their treatment was also higher in the LNG-IUD group but did not reach statistical significance (RR 1.21, 95% CI 0.80 to 1.82, 95 women, I(2) = 0%). The number of women reporting a change in menstruation was significantly higher in the LNG-IUD group (RR 37.80, 95% CI 5.40 to 264.60, 95 women, I(2) = 0%) but the number of women not completing the allocated treatment did not differ between groups (RR 0.66, 95% CI 0.08 to 5.25, I(2) = 43%).In one trial, women receiving LNG-IUD noted lower pain scores compared with women receiving gonadotrophin-releasing hormone agonists (MD -0.16, 95% CI -2.02 to 1.70, 40 women) but this did not reach statistical significance. AUTHORS' CONCLUSIONS: There is limited but consistent evidence showing that postoperative LNG-IUD use reduces the recurrence of painful periods in women with endometriosis. Further well-designed RCTs are needed to confirm these findings.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (48)
- 055 Effects of the levonorgestrel releasing intra-uterine system on uterine and ovarian volumes, endometrial thickness and dopplervelocimetry of uterine arteries, in women with pelvic endometriosis via openalex
- Combined hysteroscopic and laparoscopic findings in patients with chronic pelvic pain via openalex
- Comparative study of the influence of the levonorgestrel intra-uterine system and the GnRH analogues on cardiovascular risk markers in patients with endometriosis via openalex
- Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study via openalex
- Depressive symptoms as predictors of discontinuation of treatment of menorrhagia by levonorgestrel-releasing intrauterine system via openalex
- Diagnostic accuracy of transvaginal sonography for deep pelvic endometriosis via openalex
- Effects of the levonorgestrel-releasing intrauterine system on cardiovascular risk markers in patients with endometriosis: a comparative study with the GnRH analogue via openalex
- Effects of the levonorgestrel-releasing intrauterine system on proliferation and apoptosis in the endometrium via openalex
- Endometriosis and infertility The Practice Committee of the American Society for Reproductive Medicine via openalex
- Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density via openalex
- Is There a Role for Use of Levonorgestrel Intrauterine System in Women with Chronic Pelvic Pain? via openalex
- Laparoscopic Resection of Deep Pelvic Endometriosis with Rectosigmoid Involvement via openalex
- Laparoscopic surgery for pelvic pain associated with endometriosis via openalex
- Laparoscopy versus laparotomy in conservative surgical treatment for severe endometriosis via openalex
- Levonorgestrel-releasing intrauterine device (Lng-IUD) versus expectant management after conservative surgery for symptomatic endometriosis. A pilot study via openalex
- Levonorgestrel‐releasing intrauterine system (Mirena <sup>®</sup> ) and Depot medroxyprogesterone acetate (Depoprovera) as long‐term maintenance therapy for patients with moderate and severe endometriosis: A randomised controlled trial via openalex
- Long-term follow-up after conservative surgery for rectovaginal endometriosis via openalex
- Medical Treatment of Endometriosis via openalex
- Mirena Intra-Uterine System: Does it Improve Long Term Symptoms in Women with Chronic Pelvic Pain and/or Endometriosis after Laparoscopy? A Multicentre Randomized Controlled Trial via openalex
- Pain, quality of life and complications following the radical resection of rectovaginal endometriosis via openalex
- Postoperative Levonorgestrel-Releasing Intrauterine System for Pelvic Endometriosis-Related Pain via openalex
- Pre and post-operative medical therapy for endometriosis surgery via openalex
- Progestins for symptomatic endometriosis: a critical analysis of the evidence via openalex
- Prospective, randomized, double-blind, controlled trial of laser laparoscopy in the treatment of pelvic pain associated with minimal, mild, and moderate endometriosis via openalex
- Radical Surgery for Endometriosis via openalex
- Surgical management of endometriosis via openalex
- The diagnosis and management of infiltrating nodular recto-vaginal endometriosis via openalex
- The levonorgestrel-releasing intrauterine device reduces CA-125 serum levels in patients with endometriosis via openalex
- The levonorgestrel-releasing intrauterine system and endometriosis staging via openalex
- The role of definitive surgery and hormone replacement therapy in the treatment of endometriosis via openalex
- Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis via openalex
- Uterine Ultrasonographic Changes During Endometriosis Treatment: A Comparison Between Levonorgestrel-Releasing Intrauterine Devices and a Gonadotropin-Releasing Hormone Agonist via openalex
- W2291960606 via openalex
- W106328369 via openalex
- W2401134385 via openalex
- W6600720097 via openalex
- W6637890030 via openalex
- W6681413492 via openalex
- W6706599912 via openalex
- W6713871295 via openalex
- W2074845402 via openalex
- W7073705253 via openalex
- W2123134517 via openalex
- W2070900245 via openalex
- W2131027406 via openalex
- W2155352577 via openalex
- W2053998452 via openalex
- W2037729051 via openalex
Cited by (50)
- Clinical Management of Endometriosis in Menopause: A Narrative Review 2024
- Effects of high-intensity focused ultrasound combined with levonorgestrel-releasing intrauterine system on patients with adenomyosis 2023
- A Lifelong Impact on Endometriosis: Pathophysiology and Pharmacological Treatment 2023
- Estro-Progestins and Pain Relief in Endometriosis 2022
- Progesterone Actions and Resistance in Gynecological Disorders 2022
- Endometriosis in Adolescence 2022
- Recurrent Endometriosis 2022
- Clinical practice guidelines for endometriosis in Japan (The 3rd edition) 2022
- Levonorgestrel-releasing intrauterine device (LNG-IUD) for symptomatic endometriosis following surgery 2021
- Clinical Presentation and Management of Endometriosis-Related Hemorrhagic Ascites: A Case Report and Systematic Review of the Literature 2021
- Fibroids, Endometriosis, and Ovarian Cysts 2020
- Hormonal contraceptives and endometriosis: modern view on the problem 2020
- Preventive therapeutic options for postoperative recurrence of ovarian endometrioma: gonadotropin-releasing hormone agonist with or without levonorgestrel intrauterine system insertion 2020
- Dysmenorrhea, Endometriosis and Chronic Pelvic Pain in Adolescents 2020
- Laparoscopic surgery for endometriosis 2020
- Adenomyose 2019
- Management of Endometriomas 2019
- When more is not better: 10 ‘don’ts’ in endometriosis management. An ETIC* position statement 2019
- Peritoneal inclusion cysts treated with a levonorgestrel-releasing intrauterine system: A case report 2019
- Efficacy of levonorgestrel releasing intrauterine system as a postoperative maintenance therapy of endometriosis: A meta-analysis 2018
- Adenomyose 2018
- MRI versus laparoscopy to diagnose the main causes of chronic pelvic pain in women: a test-accuracy study and economic evaluation 2018
- The levonorgestrel‐releasing intrauterine system is associated with a reduction in dysmenorrhoea and dyspareunia, a decrease in <scp>CA</scp> 125 levels, and an increase in quality of life in women with suspected endometriosis 2018
- Endometriosis and adenomyosis 2018
- Postoperative maintenance levonorgestrel-releasing intrauterine system for symptomatic uterine adenomyoma 2018
- Evaluating the Efficacy of Levonorgestrel Intrauterine System and Danazol for Relief of Postoperative Pain in Endometriosis 2017
- Hormonal Therapy for Pelvic Pain 2017
- Endometriose — ein Überblick 2017
- Endometriosis: alternative methods of medical treatment 2015
- Current Strategies for Endometriosis Management 2015
- Évaluation et prise en charge des dysménorrhées lors d’une consultation de contraception par les médecins généralistes de Haute Normandie 2015
- Contraception and endometriosis: challenges, efficacy, and therapeutic importance 2015
- Current Management of Endometriosis An Update 2015
- Abnormal bleeding in your female patient? Consider a progestin IUD Abnormal bleeding is common in women of childbearing age. For some, insertion of a levonorgestrel-releasing IUD—easily done in a family practice setting—may be all the treatment they need. 2014
- Medical Treatment of Chronic Pelvic Pain 2014
- Endometriosis en adolescentes: un desafío terapéutico 2014
- National German Guideline (S2k): Guideline for the Diagnosis and Treatment of Endometriosis 2014
- Консенсус по ведению эндометриоза 2013
- Endometriosis: pathogenesis and treatment 2013
- Diagnosis, management, and long-term outcomes of rectovaginal endometriosis 2013
- A Critical Review of Endometriosis Pathology 2013
- Endometriose, definiert als das Vorhandensein und Proliferieren von endometriumartigem Gewebe ausser- halb des Cavum uteri, ist eine häufige Ursache für chronische Unterbauchschmerzen, Dysmenorrhö und Sterilität. Insbesondere die medikamentöse Therapie ist angesichts der immer noch ungeklärten Patho- physiologie häufig eher symptom- als kausalorientiert. 2012
- Endometriosis: diagnosis and recommended management 2012
- Endometriosis in the Adolescent Patient 2011
- Noncontraceptive Uses of Hormonal Contraception 2011
- Endometriosis: Pathogenesis and Management of Pain 2011
- Emerging indications for the levonorgestrel‐releasing intrauterine system (LNG‐IUS) 2011
- Medical Therapies: Randomized Controlled Trials/Traditional Medical Therapies 2011
- Tratamiento de la endometriosis I y II. Revisión de la literatura 2008
- Review of the safety, efficacy and patient acceptability of the levonorgestrel-releasing intrauterine system 2008
Source provenance
- europepmc
- last seen: 2026-06-13T06:22:48.782012+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:19:12.052662+00:00
License: CC0
· commercial use OK